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Introduction: Incidence of neuroendocrine tumor (NET) is increased in the last thirty years from 1.1 to 5.2
cases per 100,000 people in the United States. They can originate from the pancreatic gland and for the
majority of cases are not functioning (80%). A small percentage of functioning may produce adreno-
corticotropic hormone (ACTH) and lead to ectopic ACTH Syndrome (EAS), responsible of Cushing-
Syndrome.
Results: We present a case of a 30 year-old woman suffering from EAS due to a neoformation of the
pancreatic tail of the maximum diameter of 4 cm. The lesion was resectable at preoperatory imaging. The
patient was subjected to distal splenopancreasectomy. Histological examination showed a well-
differentiated neuroendocrine carcinoma pT3N0. The postoperative course was regular. At two years
of follow-up patient is almost completely asymptomatic for Cushing's but she has developed multiple
liver metastases, for which she began chemotherapy.
Discussion: p-NET responsible for EAS is usually malignant and the radical treatment of excision of the
lesion is not possible because they occur at the time of diagnosis with liver metastases or unresectable.
Our patient had a mass at the time of diagnosis resectable but despite radical surgery, she has developed
multiple liver metastases at two years and she was undergoing chemotherapy.
Conclusions: In agreement with previous literature we conﬁrm the aggressive nature of pancreatic tu-
mors secreting ACTH, despite radical surgery. Conversely, surgical treatment is effective on the resolution
of clinical symptoms.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Cushing's syndrome caused by ectopic production of adreno-
corticotropic hormone (ACTH or corticotropin) or EAS (Ectopic
ACTH Syndrome) is responsible for 10e20% of Cushing's syndrome
cases in the west countries [1] and 3.6% of cases in Japan [2]. Small
cell lung carcinoma is the ﬁrst cause of EAS, it is responsible of
approximately 50% of all the tumors; other causes are indolent
tumors as bronchial and thymic tumors, thyroid medullary carci-
noma and gastroenteropathic neuroendocrine tumors (GEP-NET).
A dramatic increase was reported in neuroendocrine tumors
incidence from 1.1 to 5.2 cases per 100,000 people, age-adjusted to
the US population between 1973 and 2004 [3].
Such increase presumably depends on a few factors, including a
more precise NET classiﬁcation, endoscopy diffusion for tumorsace).
by Elsevier Ltd. All rights reservedscreening and other more sensitive imaging techniques as
echoendoscopy and computerized tomography (CT) [4]. Regarding
pancreatic NETs (pNET), incidence is 0.32 cases per 100,000 people
per year, lower than lung, ileum and rectum NETs incidence
(respectively 1.35, 0.67, 0.86, per 100,000). However, autopsic
incidence of pNETs is higher (1.5% per year): this means that a
considerable group of these tumors is underdiagnosed [5].
PNETs are classiﬁed as functioning (F-) and non-functioning
(NF-), depending on the presence or not of an accompanying hor-
monal syndrome. NF-pNETs represent the majority of pNETs
(60e80%). Insulinoma and gastrinoma are the most frequent
(respectively 17 and 15%) among functioning pNETs; glucagonoma
(1%), VIPoma (2%) and somatostatinoma (<1%) are less common [6].
There also exist other tumors producing ectopic hormone such as
ACTH (1.2%) [7]. These pNETs are generally malignant except for
insulinoma. The European Neuroendocrine Tumor Society (ENETS)
and the World Health Organization (WHO) have suggested a
strategy for the diagnosis and treatment of NETs. WHO has.
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presence of metastases, the Ki-67/MIB-1 index, the histological
grade, the vascular invasion and the tumor size [8]. The WHO
classiﬁcation of NETs includes: 1) well-differentiated NETs (benign
or with an undeﬁned biological behavior), 2) well-differentiated
neuroendocrine carcinomas 3) poorly-differentiated neuroendo-
crine carcinomas. ENETS classiﬁcation places NETs in three groups:
G1, G2, G3, also according to the Ki-67/MIB-1 index and number of
nuclear mitosis, as well as the TNM classiﬁcation of large intestine
NETs [9,10]. The EAS deriving from an ACTH -secreting pNET is a
particularly aggressive disease, where metastases are observed in
the initial phases of the clinical progress, even before the devel-
opment of Cushing's syndrome clinical symptoms [11]. In patients
with this type of pNET the two-year survival rate was 40% and the
ﬁve-year survival rate was 16% [12]. Indications for surgical therapy
in presence of pNET are to relieve symptoms caused by hormonal
excess in patients with functioning tumors and to alleviate
obstructive and constitutional symptoms in patients with non-
functioning tumors.
Even though enucleation and distal pancreatectomy are the
appropriate surgical options in many cases, pan-
creatoduodenectomy could be necessary in larger size tumors or in
tumors that involve the periampullary region [13].
In this study, we report the case of a female patient who
developed EAS due to a pNET.
1.1. Case report
We present the case of a 30 year old female patient, recovered in
our ward after recovery in a medical area for suspect Cushing's
syndrome due to ectopic production of ACTH.
The patient had been suffering from asthenia, face hyper-
trichosis and declive edemas for three months. The anamnesis re-
ported a hospitalization for bleeding duodenal ulcer. A Cushingoid
phenotype is described at entrance, showing BMI 27.4, moon facies,
face hypertrichosis, striae rubra on the abdomen, arterial hyper-
tension (160/100 mmHg). Having suspected hypercholesterolemia,
ACTH was dosed (79.5 pg/ml).
Upper abdomen CT was performed on patient and multiple
hypodense formations, showing margins of the anterior surface of
pancreas tail clear and partially conﬂuent, were identiﬁed between
the greater curvature of the stomach and the medial part of the
spleen. Total body and segmentary scintigraphy using labeled
Octreotide identiﬁed a weak extraphysiologic accumulation of the
indicator in correspondence to the lesion shown by the CT.
Abdomen echography conﬁrms the presence of pancreas lesion, in
absence of hepatic metastases. The patient completed the diag-
nostic procedure with hypophysis NMR with contrast medium
(standard) and abdomen NMR, the latter describes thickening of
the pancreatic tail due to a solid neoformation of 4 cm maximum
diameter, indivisible frommultiple formations of cystic aspect with
thickened walls. The maximum global diameter of the wound is
10 cm.
The patient was therefore subjected to an operation of distal
laparotomic splenopancreasectomy. Surgical picture does not
highlight hepatic lesions, nor signs of peritoneal carcinosis. Neo-
producing lesion, that is removed, is exhibited at pancreas level.
The surgical specimen includes the tail of the pancreas measuring
8 5 3 cm in associationwith a cystic formation of 10 4 4 cm
adjacent to the spleen of 4  8 cm and of 150 g. At pancreatic pa-
renchyma level adjacent to cystic formation it is a yellowish neo-
formation of 4.5 cmmaximum of diameter that is distant 5 cm from
the pancreatic resection edge and that appears contiguous to the
spleenic parenchyma without macroscopic evidence of direct in-
vasion. Histological examination identiﬁed in pancreaticparenchyma a well-differentiated neuroendocrine carcinoma, with
cystic component and focal extension to peripancreatic adipose
tissue; mitosis 6/10 HPF, necrosis absent; extended angioinvasion;
Ki67 23% (high proliferative index). The spleen appears congested,
adherent but not inﬁltrated by neoplastic mass.
ENETS grading turned out to be G3, the stage pT3N0.
Neoplastic cell typing turned out to be pervasively positive to
Chromogranin and focally positive to ACTH.
The patient was discharged on the 11th post-operative day.
Upon discharge the patient is asymptomatic, in an euthymic mood.
After operation the patient hasn't undergone any adjuvant
therapy. After two years in absence of symptoms, we attended
Cushing's syndrome relapse with abdomen algia, asthenia and face
hypertrichosis.
Abdominal TC shows: 7 hepatic lesions with a maximum
diameter of 7.5 cm, most likely of a secondary nature. She under-
went multiple TACE, which resulted ineffective.
On March 2013 she started chemotherapy with Capecitabine
and Temozolamide.
2. Discussion
pNETs rarely produce ACTHwith Cushing's syndrome symptoms.
pNETs that determineEAS represent less than1.2%of all pNETs in the
Japanese population [4] and around 3.6% of all causes of EAS [2].
EAS-pNETs are usuallymalignant and theyoftenpresent themselves
with hepatic metastases at the time of diagnosis [8]. Because of the
rapid disease progression, EAS-pNETs prognosis is low.
Usually pNETs affect more frequently female gender and localize
in the head and body of the pancreas.
On average they measure 4.6 cm (2.5e7) [14].
In many cases the source of ectopic secretion of ACTH remains
hidden for several years, in spite of multiple attempts of tumor
localization. Signs and symptoms include increase in weight, cen-
tral obesity, asthenia, glucose intolerance and hypertension. All
patients have high levels of plasmatic and urinary cortisol [15e18].
Optimal treatment consists in localization and surgical exeresis of
the tumor. Unfortunately, pancreatic ACTH-secerning tumors often
appear with non-resectable hepatic metastases. Bilateral supra-
renalectomy is often used with palliative intent to control symp-
toms of these patients [19].
The patient presented in the clinical case, even though not
showing hepatic metastases during diagnosis, developed second-
ariness two years after surgical operation. Actual guide lines sug-
gest chemotherapy as standard for metastatic NETs [9], although
underlining that CT has aweak impact on patient survival rate, even
if it obtains a good control of disease.
3. Conclusion
According to literature in our case we noticed a remission of
endocrine symptoms after exeresis of tumoral mass. pNETs emerge
as tumors characterized by marked biological aggressiveness. In
our experience the disease represented itself with ACTH-secerning
hepatic secondariness two years after diagnosis and after operation
on primitive neoplasia.
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